Other
Margaret Ragni
Total Trials
6
Recruiting
0
Active
0
Completed
1
Success Rate
16.7%-70% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
Failure Rate
83.3%
5 terminated/withdrawn out of 6 trials
Success Rate
16.7%
-69.8% vs industry average
Late-Stage Pipeline
67%
4 trials in Phase 3/4
Results Transparency
500%
5 of 1 completed trials have results
Key Signals
5 with results
Enrollment Performance
Analytics
Phase 3
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 3(4)
Phase 2(2)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT02606045Phase 3Terminated
Minimize Menorrhagia in Women With Von Willebrand Disease
Role: lead
NCT04303559Phase 3Terminated
The Hemophilia Inhibitor Prevention Trial
Role: lead
NCT04303572Phase 3Terminated
The Hemophilia Inhibitor Eradication Trial
Role: lead
NCT02196207Phase 3Withdrawn
Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
Role: lead
NCT00524225Phase 2Terminated
IL-11 in Adults With Von Willebrand Disease Undergoing Surgery
Role: lead
NCT00524342Phase 2Completed
IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Role: lead
All 6 trials loaded